5/16
11:00 am
cdtx
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Medium
Report
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
5/16
08:15 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
5/15
04:32 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/15
04:20 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Medium
Report
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
5/15
04:09 pm
cdtx
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules [Yahoo! Finance]
Medium
Report
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules [Yahoo! Finance]
5/15
04:01 pm
cdtx
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
Medium
Report
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
5/15
11:00 am
cdtx
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
5/14
01:19 pm
cdtx
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
Low
Report
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
5/15/2024
04:09 pm
CDTX
cidara therapeutics, inc.
MISS
Report
-6.4%
cidara therapeutics, inc.
11/2/2023
04:15 pm
CDTX
cidara therapeutics, inc.
BEAT
Report
-6.3%
cidara therapeutics, inc.
8/3/2023
04:08 pm
CDTX
cidara therapeutics, inc.
MISS
Report
-2.4%
cidara therapeutics, inc.
5/15
04:30 pm
cdtx
Form 8-K Cidara Therapeutics, For: May 15
Medium
Report
Form 8-K Cidara Therapeutics, For: May 15
5/15
04:21 pm
cdtx
Form 10-Q Cidara Therapeutics, For: Mar 31
Medium
Report
Form 10-Q Cidara Therapeutics, For: Mar 31
5/6
06:15 am
cdtx
Form D Cidara Therapeutics,
High
Report
Form D Cidara Therapeutics,
5/3
08:01 am
cdtx
Form 8-K Cidara Therapeutics, For: May 03
Low
Report
Form 8-K Cidara Therapeutics, For: May 03
4/30
04:38 pm
cdtx
Form 4 Cidara Therapeutics, For: Apr 26 Filed by: Shah Rajeev M.
Low
Report
Form 4 Cidara Therapeutics, For: Apr 26 Filed by: Shah Rajeev M.
4/30
04:35 pm
cdtx
Form 3 Cidara Therapeutics, For: Apr 24 Filed by: Shah Rajeev M.
Low
Report
Form 3 Cidara Therapeutics, For: Apr 24 Filed by: Shah Rajeev M.
4/30
04:12 pm
cdtx
Form 4 Cidara Therapeutics, For: Apr 26 Filed by: Spencer Ryan
Low
Report
Form 4 Cidara Therapeutics, For: Apr 26 Filed by: Spencer Ryan
4/30
04:11 pm
cdtx
Form 3 Cidara Therapeutics, For: Apr 24 Filed by: Spencer Ryan
Low
Report
Form 3 Cidara Therapeutics, For: Apr 24 Filed by: Spencer Ryan
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
9/3
Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?
-22.6%
7/29
Form 8-K Cidara Therapeutics, For: Jul 29
-14.7%
9/3
Cidara Therapeutics Inc (NASDAQ: CDTX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating.
-13.5%
1/13
Form 8-K Cidara Therapeutics, For: Jan 13
-10.8%
4/7
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
-7.8%
2/21
Form SC 13G Cidara Therapeutics, Filed by: Stonepine Capital Management, LLC
-7.4%
1/10
Cidara Therapeutics Announces Proposed Rights Offering
-6.7%
7/29
Form 8-K Cidara Therapeutics, For: Jul 29
-6.1%
4/28
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
-6.0%
10/1
Form 4 Cidara Therapeutics, For: Sep 27 Filed by: Oien Jessica
-5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register